Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03141177 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03141177 · ClinicalTrials.gov record · last posted 2026-08-24

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Name: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — clinical trial record (NCT03141177)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CheckMate 9ER

StatusCompleted

PhasePhase 3

SponsorBristol-Myers Squibb

Started2017-07-23

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Protocol amendment history 2 changes detected by DataLookout

2026-08-25

Trial completed

2026-08-25

Completion pushed: 2026-01-16 → 2026-04-01

Trial Details

NCT Number	NCT03141177
Lead Sponsor	Bristol-Myers Squibb Collaborators: Exelixis, Ono Pharmaceutical Co., Ltd.
Conditions	Renal Cell Carcinoma
Enrollment	701 participants
Start Date	2017-07-23
Primary Completion	2020-02-12 (estimated)
Study Completion	2026-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-24